Related Party Transactions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 | |||
| Related Party Transactions [Abstract] | |||
| Related Party Transactions |
The Company has entered into various research, development, license and supply agreements with Pharmsynthez, a related party whose relationship, ownership, and nature of transactions is disclosed within other sections of these footnotes. Please refer to Note 4, Significant Strategic Collaborations for details on these arrangements.
During the fourth quarter of 2024, the Company entered into a clinical trial services agreement with PeriNess Ltd. (“PeriNess”) to advance the Company’s development program for its systemic DNase I technology in Israeli medical centers. One of our directors, Dr. Dmitry Genkin, is a significant shareholder of PeriNess and another of our directors, Mr. Moshe Mizrahy, is a majority shareholder and director of PeriNess. The Company expensed approximately $123,000 and $50,000 under this agreement during the years ended December 31, 2025 and December 31, 2024, respectively. As of December 31, 2025 and 2024, approximately $50,000 was recorded as an advanced payment and included in prepaid expenses and other current assets within the consolidated balance sheet in both years. In addition, and approximately $28,000 and $8,000 was reflected in accounts payable on the December 31, 2025 and 2024 consolidated balance sheet, respectively.
During the first quarter of 2025, the Company entered into a Consulting Agreement with Dr. Dmitry Genkin, Chairman of our Board, to provide consulting services related to the Company’s DNase-based oncology program. This agreement was effective January 1, 2025 and the Company paid Dr. Genkin approximately $0.4 million during the year ended December 31, 2025, of which approximately $30,000 was reflected within accounts payable as of December 31, 2025. Dr. Genkin does not receive any fees for his service as a member of the Board. |